| 05/05/2026 7:32 AM | Gemini Therapeutics (1816736) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/05/2026 7:33 AM | Gemini Therapeutics (1816736) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 04/28/2026 4:20 PM | Gemini Therapeutics (1816736) Filer | Form ARS | |
| 04/28/2026 4:02 PM | Gemini Therapeutics (1816736) Filer | Form DEF 14A | |
| 04/28/2026 4:06 PM | Gemini Therapeutics (1816736) Filer | Form DEFA14A | |
| 04/15/2026 3:53 PM | Gemini Therapeutics (1816736) Issuer Franchi Jean M. (1653053) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 4:05 PM | Gemini Therapeutics (1816736) Issuer Savage William Jacob (1951852) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/13/2026 3:37 PM | Gemini Therapeutics (1816736) Subject Savage William Jacob (1951852) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/04/2026 3:55 PM | Gemini Therapeutics (1816736) Issuer Savage William Jacob (1951852) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/02/2026 3:32 PM | Gemini Therapeutics (1816736) Subject Savage William Jacob (1951852) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/26/2026 8:16 AM | Gemini Therapeutics (1816736) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
Get the Latest News and Ratings for GMTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/26/2026 7:32 AM | Gemini Therapeutics (1816736) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/26/2026 7:36 AM | Gemini Therapeutics (1816736) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/25/2026 3:29 PM | Gemini Therapeutics (1816736) Subject Franchi Jean M. (1653053) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/19/2026 4:42 PM | Gemini Therapeutics (1816736) Issuer Franchi Jean M. (1653053) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/18/2026 3:41 PM | Gemini Therapeutics (1816736) Subject Franchi Jean M. (1653053) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/17/2026 8:20 PM | Gemini Therapeutics (1816736) Issuer Khara Rahul (1951850) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 8:03 PM | Gemini Therapeutics (1816736) Issuer Quisel John D (1586788) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 8:05 PM | Gemini Therapeutics (1816736) Issuer Yu Jonathan Yen-Wen (1951849) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 8:09 PM | Gemini Therapeutics (1816736) Issuer Savage William Jacob (1951852) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 8:15 PM | Gemini Therapeutics (1816736) Issuer Stephenson Pamela (1767650) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 7:46 PM | Gemini Therapeutics (1816736) Subject Yu Jonathan Yen-Wen (1951849) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/17/2026 7:51 PM | Gemini Therapeutics (1816736) Subject Savage William Jacob (1951852) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/17/2026 7:54 PM | Gemini Therapeutics (1816736) Subject Stephenson Pamela (1767650) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/17/2026 7:57 PM | Gemini Therapeutics (1816736) Subject Khara Rahul (1951850) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/17/2026 7:38 PM | Gemini Therapeutics (1816736) Subject Quisel John D (1586788) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/17/2026 7:43 PM | Gemini Therapeutics (1816736) Subject Franchi Jean M. (1653053) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/17/2026 6:42 AM | Gemini Therapeutics (1816736) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/11/2026 6:46 PM | Gemini Therapeutics (1816736) Issuer Stephenson Pamela (1767650) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/11/2026 6:50 PM | Gemini Therapeutics (1816736) Issuer Khara Rahul (1951850) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/11/2026 6:34 PM | Gemini Therapeutics (1816736) Issuer Yu Jonathan Yen-Wen (1951849) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/11/2026 6:40 PM | Gemini Therapeutics (1816736) Issuer Savage William Jacob (1951852) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/11/2026 6:26 PM | Gemini Therapeutics (1816736) Issuer Franchi Jean M. (1653053) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/11/2026 6:12 PM | Gemini Therapeutics (1816736) Issuer Quisel John D (1586788) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/21/2026 5:55 PM | Gemini Therapeutics (1816736) Issuer Khara Rahul (1951850) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/12/2026 7:37 AM | Gemini Therapeutics (1816736) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/07/2026 3:53 PM | Gemini Therapeutics (1816736) Subject RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by | Form SCHEDULE 13G | |
| 01/05/2026 7:02 PM | Gemini Therapeutics (1816736) Issuer Khara Rahul (1951850) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/02/2026 3:30 PM | Gemini Therapeutics (1816736) Subject Khara Rahul (1951850) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 7:50 PM | Gemini Therapeutics (1816736) Issuer Savage William Jacob (1951852) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/19/2025 5:16 PM | Gemini Therapeutics (1816736) Issuer Quisel John D (1586788) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
|
| 12/18/2025 5:14 PM | Bitterman Kevin (1591747) Reporting Gemini Therapeutics (1816736) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/17/2025 7:07 PM | Atlas Venture Fund X, L.P. (1628098) Filed by Gemini Therapeutics (1816736) Subject | Form SCHEDULE 13D/A | |
| 12/17/2025 6:48 PM | AI DMI LLC (1890993) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/17/2025 4:05 PM | Atlas Venture Fund X, L.P. (1628098) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/17/2025 4:06 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/17/2025 4:07 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/17/2025 4:08 PM | Atlas Venture Fund XII, L.P. (1812049) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/16/2025 8:43 PM | Bitterman Kevin (1591747) Reporting Gemini Therapeutics (1816736) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/16/2025 8:31 PM | Gemini Therapeutics (1816736) Issuer Savage William Jacob (1951852) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/16/2025 5:27 PM | AI DMI LLC (1890993) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/16/2025 4:15 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/16/2025 4:16 PM | Atlas Venture Fund X, L.P. (1628098) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/16/2025 4:17 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/16/2025 4:18 PM | Atlas Venture Fund XII, L.P. (1812049) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/16/2025 4:18 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/16/2025 4:03 PM | Atlas Venture Fund X, L.P. (1628098) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/16/2025 3:56 PM | Atlas Venture Associates XII, L.P. (1845875) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/16/2025 3:59 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 6:52 PM | AI DMI LLC (1890993) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 5:50 PM | Atlas Venture Fund X, L.P. (1628098) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 5:56 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 5:56 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 5:44 PM | Atlas Venture Associates XII, L.P. (1845875) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 4:40 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 4:45 PM | Bitterman Kevin (1591747) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 4:49 PM | Gemini Therapeutics (1816736) Issuer Quisel John D (1586788) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/15/2025 4:34 PM | Atlas Venture Fund X, L.P. (1628098) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 4:35 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 4:37 PM | Atlas Venture Fund XII, L.P. (1812049) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/15/2025 3:14 PM | Gemini Therapeutics (1816736) Subject Savage William Jacob (1951852) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/12/2025 8:50 PM | AI DMI LLC (1890993) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/12/2025 4:10 PM | Atlas Venture Fund X, L.P. (1628098) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/12/2025 4:11 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/12/2025 4:13 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/12/2025 4:15 PM | Atlas Venture Fund XII, L.P. (1812049) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/11/2025 3:25 PM | Gemini Therapeutics (1816736) Subject Quisel John D (1586788) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/08/2025 7:40 AM | Gemini Therapeutics (1816736) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/13/2025 7:22 PM | Gemini Therapeutics (1816736) Issuer Yu Jonathan Yen-Wen (1951849) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/12/2025 5:56 AM | Gemini Therapeutics (1816736) Subject Yu Jonathan Yen-Wen (1951849) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/06/2025 7:33 AM | Gemini Therapeutics (1816736) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/06/2025 7:34 AM | Gemini Therapeutics (1816736) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/05/2025 10:30 AM | Gemini Therapeutics (1816736) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 10/24/2025 3:01 PM | Access Industries Holdings LLC (1391297) Reporting ACCESS INDUSTRIES MANAGEMENT, LLC (1508226) Reporting AI DMI LLC (1890993) Reporting Blavatnik Len (1326628) Reporting Gemini Therapeutics (1816736) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/22/2025 8:44 PM | AI DMI LLC (1890993) Filed by Gemini Therapeutics (1816736) Subject | Form SCHEDULE 13D/A | |
| 10/22/2025 8:11 AM | Gemini Therapeutics (1816736) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/21/2025 4:13 PM | Gemini Therapeutics (1816736) Filer | Form 424B5 | |
| 10/20/2025 7:54 PM | Gemini Therapeutics (1816736) Subject ORBIMED ADVISORS LLC (1055951) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/20/2025 7:47 PM | Gemini Therapeutics (1816736) Subject ORBIMED ADVISORS LLC (1055951) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/20/2025 7:52 PM | Gemini Therapeutics (1816736) Subject ORBIMED ADVISORS LLC (1055951) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/20/2025 6:09 AM | Gemini Therapeutics (1816736) Filer | Form 424B5 | |
|
| 10/20/2025 5:38 AM | Gemini Therapeutics (1816736) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/17/2025 4:23 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/17/2025 4:26 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/17/2025 3:41 PM | Bitterman Kevin (1591747) Reporting Gemini Therapeutics (1816736) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/17/2025 3:42 PM | Atlas Venture Fund X, L.P. (1628098) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/17/2025 7:43 AM | Gemini Therapeutics (1816736) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/16/2025 3:46 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/16/2025 3:46 PM | Atlas Venture Fund X, L.P. (1628098) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/15/2025 4:00 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Gemini Therapeutics (1816736) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |